EATRIS: providing the right tools, at the right time, for vaccine development in a pandemic
Vaccine Insights 2022; 1(3), 131–137
DOI: 10.18609/vac.2022.022
Published: 26 June 2022
Commentary
As society continues to take its first cautious steps out of the COVID-19 pandemic, researchers, including vaccine developers, continue to reflect on the challenges that they faced and overcame together during the last 2 years and the improvements necessary for better pandemic preparedness in future. Now more than ever, the world is recognizing the importance of vaccines, and the European Research Infrastructure for Translational Medicine (EATRIS) and its infrastructure partners across Europe and beyond have strived to accelerate promising candidates through the R&D pipeline, by offering innovative services to vaccine developers in academic and industry settings.